Shattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have earned an average recommendation of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.00.

A number of equities analysts have weighed in on the stock. Wall Street Zen raised shares of Shattuck Labs from a “hold” rating to a “buy” rating in a research note on Saturday. TD Cowen reaffirmed a “buy” rating on shares of Shattuck Labs in a research note on Friday, March 6th. Weiss Ratings downgraded shares of Shattuck Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 2nd. Jefferies Financial Group raised shares of Shattuck Labs to an “outperform” rating and set a $7.00 price target on the stock in a research note on Friday, June 5th. Finally, Cantor Fitzgerald assumed coverage on shares of Shattuck Labs in a research note on Monday, April 27th. They set an “overweight” rating on the stock.

Insider Buying and Selling

In other Shattuck Labs news, Director Clay B. Siegall acquired 62,500 shares of the company’s stock in a transaction dated Tuesday, June 9th. The stock was bought at an average price of $4.00 per share, with a total value of $250,000.00. Following the completion of the transaction, the director directly owned 318,608 shares of the company’s stock, valued at approximately $1,274,432. The trade was a 24.40% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Arundathy N. Pandite sold 30,000 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $6.61, for a total transaction of $198,300.00. Following the completion of the sale, the insider directly owned 166,219 shares of the company’s stock, valued at $1,098,707.59. The trade was a 15.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 8.79% of the company’s stock.

Institutional Investors Weigh In On Shattuck Labs

Several large investors have recently made changes to their positions in the business. Orbimed Advisors LLC acquired a new stake in shares of Shattuck Labs in the third quarter worth $15,072,000. NEXTBio Capital Management LP acquired a new stake in shares of Shattuck Labs in the fourth quarter worth $11,497,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Shattuck Labs in the fourth quarter worth $7,031,000. Pinnacle Associates Ltd. increased its position in shares of Shattuck Labs by 1.8% in the third quarter. Pinnacle Associates Ltd. now owns 1,388,723 shares of the company’s stock worth $3,319,000 after acquiring an additional 25,000 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in shares of Shattuck Labs in the fourth quarter worth $4,945,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Stock Performance

Shares of STTK opened at $4.33 on Wednesday. The company has a market capitalization of $332.02 million, a price-to-earnings ratio of -6.87 and a beta of 1.08. The company’s 50 day simple moving average is $6.28 and its 200 day simple moving average is $5.00. Shattuck Labs has a 1 year low of $0.71 and a 1 year high of $8.33.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. During the same quarter in the previous year, the company posted ($0.27) EPS. Equities analysts expect that Shattuck Labs will post -0.51 EPS for the current fiscal year.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.